<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32429516</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6651</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Toxins</Title><ISOAbbreviation>Toxins (Basel)</ISOAbbreviation></Journal><ArticleTitle>Neuroprotective Fragment C of Tetanus Toxin Modulates IL-6 in an ALS Mouse Model.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">330</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/toxins12050330</ELocationID><Abstract><AbstractText>Neuroinflammation plays a significant role in amyotrophic lateral sclerosis (ALS) pathology, leading to the development of therapies targeting inflammation in recent years. Our group has studied the tetanus toxin C-terminal fragment (TTC) as a therapeutic molecule, showing neuroprotective properties in the SOD1G93A mouse model. However, it is unknown whether TTC could have some effect on inflammation. The objective of this study was to assess the effect of TTC on the regulation of inflammatory mediators to elucidate its potential role in modulating inflammation occurring in ALS. After TTC treatment in SOD1G93A mice, levels of eotaxin-1, interleukin (IL)-2, IL-6 and macrophage inflammatory protein (MIP)-1 alpha (&#x3b1;) and galectin-1 were analyzed by immunoassays in plasma samples, whilst protein expression of caspase-1, IL-1&#x3b2;, IL-6 and NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) was measured in the spinal cord, extensor digitorum longus (EDL) muscle and soleus (SOL) muscle. The results showed reduced levels of IL-6 in spinal cord, EDL and SOL in treated SOD1G93A mice. In addition, TTC showed a different role in the modulation of NLRP3 and caspase-1 depending on the tissue analyzed. In conclusion, our results suggest that TTC could have a potential anti-inflammatory effect by reducing IL-6 levels in tissues drastically affected by the disease. However, further research is needed to study more in depth the anti-inflammatory effect of TTC in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Martinez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-7277-4318</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Torre</LastName><ForeName>Miriam</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7955-7164</Identifier><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Mar&#xed;a J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaragoza</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguilera</LastName><ForeName>Jos&#xe9;</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9906-8034</Identifier><AffiliationInfo><Affiliation>Institut de Neuroci&#xe8;ncies and Departament de Bioqu&#xed;mica i de Biologia Molecular, Facultat de Medicina, Universitat Aut&#xf2;noma de Barcelona (UAB) and Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 08193 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Ana C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary, Institute for Health Research Aragon (IIS Arag&#xf3;n), AgriFood Institute of Aragon (IA2), Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PI17/00949</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country>International</Country></Grant><Grant><GrantID>.</GrantID><Agency>Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa"</Agency><Country>International</Country></Grant><Grant><GrantID>.</GrantID><Agency>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED-612)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Toxins (Basel)</MedlineTA><NlmUniqueID>101530765</NlmUniqueID><ISSNLinking>2072-6651</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013744">Tetanus Toxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C577686">interleukin-6, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C040635">tetanus toxin fragment C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="C000628184">Casp1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.36</RegistryNumber><NameOfSubstance UI="D020170">Caspase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020170" MajorTopicYN="N">Caspase 1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013744" MajorTopicYN="N">Tetanus Toxin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A mouse model</Keyword><Keyword MajorTopicYN="N">TTC</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32429516</ArticleId><ArticleId IdType="pmc">PMC7290364</ArticleId><ArticleId IdType="doi">10.3390/toxins12050330</ArticleId><ArticleId IdType="pii">toxins12050330</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scott A. Drug Therapy: On the Treatment Trail for ALS. Nature. 2017;550:S120&#x2013;S121. doi: 10.1038/550S120a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/550S120a</ArticleId><ArticleId IdType="pubmed">29045376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M. How Neuroinflammation Contributes to Neurodegeneration. Science. 2016;353:777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Simpson E.P., Appel S.H. Neuroinflammatory Mechanisms in Amyotrophic Lateral Sclerosis Pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Wang F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. Front. Immunol. 2017;8:1005. doi: 10.3389/fimmu.2017.01005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martinez L., Calvo A.C., Munoz M.J., Osta R. Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis? Int. J. Mol. Sci. 2019;20 doi: 10.3390/ijms20112759.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112759</ArticleId><ArticleId IdType="pmc">PMC6600567</ArticleId><ArticleId IdType="pubmed">31195629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellezza I., Grottelli S., Costanzi E., Scarpelli P., Pigna E., Morozzi G., Mezzasoma L., Peirce M.J., Moresi V., Adamo S., et al. Peroxynitrite Activates the NLRP3 Inflammasome Cascade in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2018;55:2350&#x2013;2361. doi: 10.1007/s12035-017-0502-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0502-x</ArticleId><ArticleId IdType="pubmed">28357805</ArticleId></ArticleIdList></Reference><Reference><Citation>Debye B., Schmulling L., Zhou L., Rune G., Beyer C., Johann S. Neurodegeneration and NLRP3 Inflammasome Expression in the Anterior Thalamus of SOD1(G93A) ALS Mice. Brain Pathol. 2018;28:14&#x2013;27. doi: 10.1111/bpa.12467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12467</ArticleId><ArticleId IdType="pubmed">27880990</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo A., Giacoppo S., Bramanti P., Mazzon E. NLRP3 Inflammasome Activation in a Transgenic Amyotrophic Lateral Sclerosis Model. Inflammation. 2018;41:93&#x2013;103. doi: 10.1007/s10753-017-0667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0667-5</ArticleId><ArticleId IdType="pubmed">28936769</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Hara H., Nunez G. Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem. Sci. 2016;41:1012&#x2013;1021. doi: 10.1016/j.tibs.2016.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2016.09.002</ArticleId><ArticleId IdType="pmc">PMC5123939</ArticleId><ArticleId IdType="pubmed">27669650</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaelson N., Facciponte D., Bradley W., Stommel E. Cytokine Expression Levels in ALS: A Potential Link between Inflammation and BMAA-Triggered Protein Misfolding. Cytokine Growth Factor Rev. 2017;37:81&#x2013;88. doi: 10.1016/j.cytogfr.2017.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2017.05.001</ArticleId><ArticleId IdType="pubmed">28532674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.H., Oh K.W., Jin H.K., Bae J.S. Immune Inflammatory Modulation as a Potential Therapeutic Strategy of Stem Cell Therapy for ALS and Neurodegenerative Diseases. BMB Rep. 2018;51:545&#x2013;546. doi: 10.5483/BMBRep.2018.51.11.255.</Citation><ArticleIdList><ArticleId IdType="doi">10.5483/BMBRep.2018.51.11.255</ArticleId><ArticleId IdType="pmc">PMC6283021</ArticleId><ArticleId IdType="pubmed">30463642</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff J.R., Beers D.R., Zhao W., Pleitez M., Simpson E.P., Berry J.D., Cudkowicz M.E., Appel S.H. Expanded Autologous Regulatory T-Lymphocyte Infusions in ALS: A Phase I, First-in-Human Study. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e465. doi: 10.1212/NXI.0000000000000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000465</ArticleId><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune Dysregulation in Amyotrophic Lateral Sclerosis: Mechanisms and Emerging Therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen J.M., Olivan S., Osta R. Tetanus Toxin C-Fragment: The Courier and the Cure? Toxins. 2010;2:2622&#x2013;2644. doi: 10.3390/toxins2112622.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/toxins2112622</ArticleId><ArticleId IdType="pmc">PMC3153173</ArticleId><ArticleId IdType="pubmed">22069568</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A.C., Moreno-Igoa M., Mancuso R., Manzano R., Olivan S., Munoz M.J., Penas C., Zaragoza P., Navarro X., Osta R. Lack of a Synergistic Effect of a Non-Viral ALS Gene Therapy Based on BDNF and a TTC Fusion Molecule. Orphanet J. Rare Dis. 2011;6:10. doi: 10.1186/1750-1172-6-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-6-10</ArticleId><ArticleId IdType="pmc">PMC3072305</ArticleId><ArticleId IdType="pubmed">21418619</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Igoa M., Calvo A.C., Penas C., Manzano R., Olivan S., Munoz M.J., Mancuso R., Zaragoza P., Aguilera J., Navarro X., et al. Fragment C of Tetanus Toxin, More than a Carrier. Novel Perspectives in Non-Viral ALS Gene Therapy. J. Mol. Med. 2010;88:297&#x2013;308. doi: 10.1007/s00109-009-0556-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-009-0556-y</ArticleId><ArticleId IdType="pubmed">19921501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriza J., Moreno-Igoa M., Calvo A.C., Yague G., Palacio J., Miana-Mena F.J., Munoz M.J., Zaragoza P., Brulet P., Osta R. A Genetic Fusion GDNF-C Fragment of Tetanus Toxin Prolongs Survival in a Symptomatic Mouse ALS Model. Restor. Neurol. Neurosci. 2008;26:459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">19096133</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J., Smith A.J., Kuzmin-Nichols N., Zesiewicz T.A., Jahan I., Shytle R.D., Kim S.H., Sanberg C.D., Vu T.H., Gooch C.L., et al. Humoral Factors in ALS Patients during Disease Progression. J. Neuroinflamm. 2015;12:127. doi: 10.1186/s12974-015-0350-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Steyn F.J., Huang L., Mantovani S., Pfluger C.M., Woodruff T.M., O&#x2019;Sullivan J.D., Henderson R.D., McCombe P.A. Altered Expression of Metabolic Proteins and Adipokines in Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2015;357:22&#x2013;27. doi: 10.1016/j.jns.2015.06.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.06.053</ArticleId><ArticleId IdType="pubmed">26198021</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.H., Allen K., Oei F., Leoni E., Kuhle J., Tree T., Fratta P., Sharma N., Sidle K., Howard R., et al. Systemic Inflammatory Response and Neuromuscular Involvement in Amyotrophic Lateral Sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Garcon G., Patin F., Veyrat-Durebex C., Boyer J., Devos D., Vourc&#x2019;h P., Andres C.R., Corcia P. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. Can. J. Neurol. Sci. 2017;44:90&#x2013;95. doi: 10.1017/cjn.2016.284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2016.284</ArticleId><ArticleId IdType="pubmed">27774920</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased Peripheral Blood Inflammatory Cytokine Levels in Amyotrophic Lateral Sclerosis: A Meta-Analysis Study. Sci. Rep. 2017;7:1&#x2013;9. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Prado L.G.R., Rocha N.P., de Souza L.C., Bicalho I.C.S., Gomez R.S., Vidigal-Lopes M., Braz N.F.T., Vieira E.L.M., Teixeira A.L. Longitudinal Assessment of Clinical and Inflammatory Markers in Patients with Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2018;394:69&#x2013;74. doi: 10.1016/j.jns.2018.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.08.033</ArticleId><ArticleId IdType="pubmed">30219498</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Xia K., Chen L., Fan D. Increased Interleukin-6 Levels in the Astrocyte-Derived Exosomes of Sporadic Amyotrophic Lateral Sclerosis Patients. Front. Neurosci. 2019;13:574. doi: 10.3389/fnins.2019.00574.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00574</ArticleId><ArticleId IdType="pmc">PMC6560167</ArticleId><ArticleId IdType="pubmed">31231184</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martinez L., de la Torre M., Toivonen J.M., Zaragoza P., Garcia-Redondo A., Calvo A.C., Osta R. Circulating Cytokines could Not be Good Prognostic Biomarkers in a Mouse Model of Amyotrophic Lateral Sclerosis. Front. Immunol. 2019;10:801. doi: 10.3389/fimmu.2019.00801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00801</ArticleId><ArticleId IdType="pmc">PMC6473074</ArticleId><ArticleId IdType="pubmed">31031774</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., Destee A., Tonnel A.B., Lassalle P., Just N. Elevated IL-6 and TNF-Alpha Levels in Patients with ALS: Inflammation Or Hypoxia? Neurology. 2005;65:1958&#x2013;1960. doi: 10.1212/01.wnl.0000188907.97339.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Pronto-Laborinho A., Pinto S., Gromicho M., Pereira M., Swash M., de Carvalho M. Interleukin-6 and Amyotrophic Lateral Sclerosis. J. Neurol. Sci. 2019;398:50&#x2013;53. doi: 10.1016/j.jns.2019.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.026</ArticleId><ArticleId IdType="pubmed">30682521</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X.Y., Zhang S.P., Cao C., Loh Y.P., Cheng Y. Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-Analysis. JAMA Neurol. 2016;73:1316&#x2013;1324. doi: 10.1001/jamaneurol.2016.2742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.2742</ArticleId><ArticleId IdType="pubmed">27668667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai K.S.P., Liu C.S., Rau A., Lanctot K.L., Kohler C.A., Pakosh M., Carvalho A.F., Herrmann N. Peripheral Inflammatory Markers in Alzheimer&#x2019;s Disease: A Systematic Review and Meta-Analysis of 175 Studies. J. Neurol. Neurosurg. Psychiatry. 2017;88:876&#x2013;882. doi: 10.1136/jnnp-2017-316201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316201</ArticleId><ArticleId IdType="pubmed">28794151</ArticleId></ArticleIdList></Reference><Reference><Citation>Madaro L., Passafaro M., Sala D., Etxaniz U., Lugarini F., Proietti D., Alfonsi M.V., Nicoletti C., Gatto S., De Bardi M., et al. Denervation-Activated STAT3-IL-6 Signalling in Fibro-Adipogenic Progenitors Promotes Myofibres Atrophy and Fibrosis. Nat. Cell Biol. 2018;20:917&#x2013;927. doi: 10.1038/s41556-018-0151-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-018-0151-y</ArticleId><ArticleId IdType="pmc">PMC6145844</ArticleId><ArticleId IdType="pubmed">30050118</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi F., Vallarola A., Violatto M.B., Talamini L., Freschi M., De Gioia R., Capelli C., Agostini A., Moscatelli D., Tortarolo M., et al. Multiple Intracerebroventricular Injections of Human Umbilical Cord Mesenchymal Stem Cells Delay Motor Neurons Loss but Not Disease Progression of SOD1G93A Mice. Stem Cell Res. 2017;25:166&#x2013;178. doi: 10.1016/j.scr.2017.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2017.11.005</ArticleId><ArticleId IdType="pubmed">29154076</ArticleId></ArticleIdList></Reference><Reference><Citation>Korhonen P., Pollari E., Kanninen K.M., Savchenko E., Lehtonen S., Wojciechowski S., Pomeshchik Y., Van Den Bosch L., Goldsteins G., Koistinaho J., et al. Long-Term Interleukin-33 Treatment Delays Disease Onset and Alleviates Astrocytic Activation in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. IBRO Rep. 2019;6:74&#x2013;86. doi: 10.1016/j.ibror.2019.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibror.2019.01.005</ArticleId><ArticleId IdType="pmc">PMC6348738</ArticleId><ArticleId IdType="pubmed">30705990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J., Zheng Y., Yang J., Zhang J., Cao W., Chen X., Fang S. Resveratrol Alleviates Inflammatory Injury and Enhances the Apoptosis of Fibroblastlike Synoviocytes Via Mitochondrial Dysfunction and ER Stress in Rats with Adjuvant Arthritis. Mol. Med. Rep. 2019;20:463&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580038</ArticleId><ArticleId IdType="pubmed">31180523</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Lindberg R.L., Regeniter A., Mehling M., Steck A.J., Kappos L., Czaplinski A. Increased Levels of Inflammatory Chemokines in Amyotrophic Lateral Sclerosis. Eur. J. Neurol. 2009;16:771&#x2013;774. doi: 10.1111/j.1468-1331.2009.02560.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Gao L., Wu X., Zhang Y., Zang D. Increased Levels of MIP-1alpha in CSF and Serum of ALS. Acta Neurol. Scand. 2016;134:94&#x2013;100. doi: 10.1111/ane.12513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12513</ArticleId><ArticleId IdType="pubmed">26427609</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J., Yang X., Gao L., Zang D. Evaluating the Levels of CSF and Serum Factors in ALS. Brain Behav. 2017;7:e00637. doi: 10.1002/brb3.637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F., Molawi K., Zychlinsky A. Mutant Superoxide Dismutase 1-Induced IL-1beta Accelerates ALS Pathogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S., Heitzer M., Kanagaratnam M., Goswami A., Rizo T., Weis J., Troost D., Beyer C. NLRP3 Inflammasome is Expressed by Astrocytes in the SOD1 Mouse Model of ALS and in Human Sporadic ALS Patients. Glia. 2015;63:2260&#x2013;2273. doi: 10.1002/glia.22891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22891</ArticleId><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann S., Esch E., Hartmann P., Goswami A., Nikolin S., Weis J., Beyer C., Johann S. Expression Profile of Pattern Recognition Receptors in Skeletal Muscle of SOD1((G93A)) Amyotrophic Lateral Sclerosis (ALS) Mice and Sporadic ALS Patients. Neuropathol. Appl. Neurobiol. 2018;44:606&#x2013;627. doi: 10.1111/nan.12483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12483</ArticleId><ArticleId IdType="pubmed">29575052</ArticleId></ArticleIdList></Reference><Reference><Citation>Okumura N., Hashida-Okumura A., Kita K., Matsubae M., Matsubara T., Takao T., Nagai K. Proteomic Analysis of Slow- and Fast-Twitch Skeletal Muscles. Proteomics. 2005;5:2896&#x2013;2906. doi: 10.1002/pmic.200401181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200401181</ArticleId><ArticleId IdType="pubmed">15981298</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia W.H., Wang N.Q., Yin L., Chen X., Hou B.Y., Qiang G.F., Chan C.B., Yang X.Y., Du G.H. Effect of Skeletal Muscle Phenotype and Gender on Fasting-Induced Myokine Expression in Mice. Biochem. Biophys. Res. Commun. 2019;514:407&#x2013;414. doi: 10.1016/j.bbrc.2019.04.155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.04.155</ArticleId><ArticleId IdType="pubmed">31056256</ArticleId></ArticleIdList></Reference><Reference><Citation>Grottelli S., Mezzasoma L., Scarpelli P., Cacciatore I., Cellini B., Bellezza I. Cyclo(His-Pro) Inhibits NLRP3 Inflammasome Cascade in ALS Microglial Cells. Mol. Cell. Neurosci. 2019;94:23&#x2013;31. doi: 10.1016/j.mcn.2018.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.11.002</ArticleId><ArticleId IdType="pubmed">30439413</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer M., Kaiser S., Kanagaratnam M., Zendedel A., Hartmann P., Beyer C., Johann S. Administration of 17beta-Estradiol Improves Motoneuron Survival and Down-Regulates Inflammasome Activation in Male SOD1(G93A) ALS Mice. Mol. Neurobiol. 2017;54:8429&#x2013;8443. doi: 10.1007/s12035-016-0322-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0322-4</ArticleId><ArticleId IdType="pubmed">27957680</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Toivonen J.M., Olivan S., Calvo A.C., Moreno-Igoa M., Munoz M.J., Zaragoza P., Garcia-Redondo A., Osta R. Altered Expression of Myogenic Regulatory Factors in the Mouse Model of Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2011;8:386&#x2013;396. doi: 10.1159/000324159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000324159</ArticleId><ArticleId IdType="pubmed">21346327</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Toivonen J.M., Calvo A.C., Munoz M.J., Zaragoza P., Osta R. Housekeeping Gene Expression in Myogenic Cell Cultures from Neurodegeneration and Denervation Animal Models. Biochem. Biophys. Res. Commun. 2011;407:758&#x2013;763. doi: 10.1016/j.bbrc.2011.03.096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.03.096</ArticleId><ArticleId IdType="pubmed">21439935</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R., Toivonen J.M., Calvo A.C., Olivan S., Zaragoza P., Munoz M.J., Montarras D., Osta R. Quantity and Activation of Myofiber-Associated Satellite Cells in a Mouse Model of Amyotrophic Lateral Sclerosis. Stem Cell. Rev. Rep. 2012;8:279&#x2013;287. doi: 10.1007/s12015-011-9268-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-011-9268-0</ArticleId><ArticleId IdType="pubmed">21537993</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>